Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Casey Batten

Sports Medicine Thousand Oaks, CA Medical Doctor

NPI 1629010327 CMS profile 1064122

1011 Rancho Conejo Blvd, Thousand Oaks, CA 91320

Open in the dashboard

General payments

$26,052

150 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Casey Batten of Thousand Oaks, CA is reported in the CMS Open Payments database as having received $26,052 across 150 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $12,031 14
2024 General $647 8
2023 General $1,201 9
2022 General $479 11
2021 General $3,617 24
2020 General $1,705 36
2019 General $6,373 48

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Casey Batten
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Casey Batten were reported at $12,031. Among 1,257 Sports Medicine profiles paid that year, the median was $114 and the middle half received between $39 and $293.

Show as a table
Year Casey Batten Sports Medicine median Middle half National median
2019 $6,373 $119 $35–$362 $163
2020 $1,705 $77 $24–$275 $114
2021 $3,617 $104 $28–$340 $132
2022 $479 $94 $31–$272 $149
2023 $1,201 $91 $34–$271 $160
2024 $647 $126 $38–$294 $164
2025 $12,031 $114 $39–$293 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Smith+Nephew, Inc. $11,735 10 payments
  2. Arthrex, Inc. $4,833 10 payments
  3. Flexion Therapeutics, Inc. $3,855 47 payments
  4. DePuy Synthes Sales Inc. $1,207 37 payments
  5. Trice Medical, Inc. $1,028 2 payments
  6. Tenex Health Inc. $1,000 1 payment
  7. Micromed Inc $500 1 payment
  8. Stryker Corporation $415 3 payments
  9. Ossur Americas., Inc $242 2 payments
  10. Djo, LLC $222 2 payments
  11. Other $1,016 35 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $10,275 2 payments
  2. Food and Beverage $5,166 134 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,500 2 payments
  4. Honoraria $3,800 3 payments
  5. Travel and Lodging $2,263 8 payments
  6. Education $49 1 payment
Products named General payments · program years 2019–2025
  1. FAST-FIX $9,510 2 payments
  2. SPATIAL FRAME $9,375 1 payment
  3. Q-FIX Sports Med Shoulder $9,375 1 payment
  4. Zilretta $3,855 47 payments
  5. ACUFEX Meniscal Root Repair $2,084 7 payments
  6. CAP-FIX $1,853 6 payments
  7. Q-FIX Extremities & Limb Restoration $1,853 6 payments
  8. NovoStitch $1,853 6 payments
  9. HEALICOIL $1,853 6 payments
  10. MONOVISC $518 11 payments
  11. Other $2,670 65 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$198,563

Of which drugs: $101,991

Medicare patients

272

Average age 73

Services billed

7,565

138 women, 134 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 63%
Ischemic heart disease 29%
Osteoporosis 21%
Depression 18%
Diabetes 17%
Cancer 17%
Atrial fibrillation 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg J3304 Office 61 4,384 $59,589
Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose J7324 Office 63 309 $29,709
Hyaluronan or derivative, monovisc, for intra-articular injection, per dose J7327 Office 11 20 $10,779
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 27 86 $476
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 46 282 $209

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

150 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record